Literature DB >> 9120814

Stereoselective pharmacokinetics of mefloquine in healthy Caucasians after multiple doses.

F Gimenez1, R A Pennie, G Koren, C Crevoisier, I W Wainer, R Farinotti.   

Abstract

Mefloquine (MQ) is a chiral antimalarial agent effective against chloroquine-resistant Plasmodium falciparum. It is commercially available as a racemic mixture of the (+) and (-) enantiomers for oral administration. The pharmacokinetics of the (+) and (-) enantiomers of MQ were studied in eight healthy volunteers after administration of a first oral dose of 250 mg of racemic MQ and at steady state after 13 repeated doses of 250 mg given at 1-week intervals. Plasma samples were collected, and concentrations of each enantiomer were determined using a previously described achiral-chiral double column-switching liquid chromatographic method. At each time point, higher plasma concentrations values were found for the (-) enantiomer (p < 0.001). At steady state, Cmax values of (-)-MQ were higher than those of (+)-MQ (1.42 +/- 0.19 versus 0.26 +/- 0.05 mg/L; p < 0.001). Similarly, the plasma concentrations 7 days after the final dose were higher for (-)-MQ (1.01 +/- 0.26 versus 0.11 +/- 0.04 mg/L; p < 0.001). AUC values at steady state were also higher for (-)-MQ (197.3 +/- 36.7 versus 30.1 +/- 8.9 mg/L x h; p < 0.001). The terminal half-life values (T1/2beta) were longer for (-)-MQ (430.4 +/- 225.2 versus 172.8 +/- 56.5 h; p < 0.001). This study shows that the pharmacokinetics of MQ is highly stereoselective.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 9120814     DOI: 10.1002/jps.2600830613

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  13 in total

1.  The enantioselective binding of mefloquine enantiomers to P-glycoprotein determined using an immobilized P-glycoprotein liquid chromatographic stationary phase.

Authors:  L Lu; F Leonessa; M T Baynham; R Clarke; F Gimenez; Y T Pham; F Roux; I W Wainer
Journal:  Pharm Res       Date:  2001-09       Impact factor: 4.200

2.  Identification of (+)-erythro-mefloquine as an active enantiomer with greater efficacy than mefloquine against Mycobacterium avium infection in mice.

Authors:  Luiz E Bermudez; Clark B Inderlied; Peter Kolonoski; Christopher B Chee; Priscilla Aralar; Mary Petrofsky; Toufan Parman; Carol E Green; Anita H Lewin; William Y Ellis; Lowell S Young
Journal:  Antimicrob Agents Chemother       Date:  2012-05-21       Impact factor: 5.191

3.  A randomized, double-blind, placebo-controlled study to investigate the safety, tolerability, and pharmacokinetics of single enantiomer (+)-mefloquine compared with racemic mefloquine in healthy persons.

Authors:  Robert Tansley; Julie Lotharius; Anthony Priestley; Fiona Bull; Stephan Duparc; Jörg Möhrle
Journal:  Am J Trop Med Hyg       Date:  2010-12       Impact factor: 2.345

4.  Crystal structure of (-)-mefloquine hydrochloride reveals consistency of configuration with biological activity.

Authors:  Jean M Karle; Isabella L Karle
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

5.  Interspecies allometric scaling of antimalarial drugs and potential application to pediatric dosing.

Authors:  S M D K Ganga Senarathna; Kevin T Batty
Journal:  Antimicrob Agents Chemother       Date:  2014-08-04       Impact factor: 5.191

6.  Population Pharmacokinetics of Mefloquine Intermittent Preventive Treatment for Malaria in Pregnancy in Gabon.

Authors:  Michael Ramharter; Matthias Schwab; Clara Menendez; Reinhold Kerb; Thorsten Lehr; Ghyslain Mombo-Ngoma; Rella Zoleko Manego; Daisy Akerey-Diop; Arti Basra; Jean-Rodolphe Mackanga; Heike Würbel; Jan-Georg Wojtyniak; Raquel Gonzalez; Ute Hofmann; Mirjam Geditz; Pierre-Blaise Matsiegui; Peter G Kremsner
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

Review 7.  Stereoselectivity in the pharmacodynamics and pharmacokinetics of the chiral antimalarial drugs.

Authors:  Dion R Brocks; Reza Mehvar
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 8.  Clinical pharmacology of artemisinin-based combination therapies.

Authors:  Polina I German; Francesca T Aweeka
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

9.  Whole blood concentrations of mefloquine enantiomers in healthy Thai volunteers.

Authors:  C Martin; F Gimenez; K N Bangchang; J Karbwang; I W Wainer; R Farinotti
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

10.  Cerebral uptake of mefloquine enantiomers with and without the P-gp inhibitor elacridar (GF1210918) in mice.

Authors:  Sylvie Barraud de Lagerie; Emmanuelle Comets; Céline Gautrand; Christine Fernandez; Daniel Auchere; Eric Singlas; France Mentre; François Gimenez
Journal:  Br J Pharmacol       Date:  2004-03-15       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.